Novel pharmacological strategies for analgesia

Annals of the Rheumatic Diseases

Volumn 55, Issue 10, 1996, Pages 715-722

  Perkins, Martin ^a   Dray, Andy ^a  

^a Sandoz Institute for Medical Research   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; BRADYKININ ANTAGONIST; CAPSAICIN; KALLIDIN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; TACHYKININ RECEPTOR ANTAGONIST;

ANALGESIA; CLINICAL TRIAL; HUMAN; PHARMACOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0029833804     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.55.10.715     Document Type: Review

References (93)

1. von Korff M, Dworkin SF, Le Resche L. Graded chronic pain states: an epidemiological evaluation. Pain 1990; 40:279-91.
2. Dray A, Urban L, Dickenson A H. Pharmacology of chronic pain. Trends Pharmacol Sci 1994;15:190-97.
3. Woolf CJ. The dorsal horn: state-dependent sensory processing and the generation of pain. In: Wall P D, Melzack R, eds. Textbook of pain, 2nd ed. Edinburgh: Churchill-Livingstone, 1994: 101-12.
4. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens and kininases. Pharmacol Rev 1992;44:1-80.
5. Hall JM. Bradykinin receptors: pharmacological properties and biological roles. Pharmacol Ther 1992;56:131-90.
6. 2 bradykinin receptor. Proc Natl Acad Sci USA 1991;88:7724-8.
7. Hess JF, Borkowski JA, Young GS, Strader CD, Ransom RW. Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor. Biochem Biophys Res Commun 1992;184:260-8.
8. 1 bradykinin receptor. J Biol Chem 1994;269:21583-6.
9. Burgess GM, Mullaney J, McNeil M, Dunn P, Rang HP. Second messengers involved in the action of bradykinin on cultured sensory neurones. J Neursoci 1989;9:3314-25.
10. Dray A, Patel IA, Perkins MN, Rueff A. Bradykinin-induced activation of nociceptors: receptor and mechanistic studies on the neonatal rat spinal cord-tail preparation in vitro. Br J Pharmacol 1992;100:656-60.
11. Mizumura K, Minagawa M, Tsujii Y, Kumazawa T. The effects of bradykinin agonists and antagonists on visceral polymodal receptor activities. Pain 1990;40:221-7.
12. Sengupta JN, Gebhart GF. Characterization of mechano-sensitive pelvic nerve afferent fibers innervating the colon of the rat. J Neurophysiol 1994;71:2046-60.
13. Ferreira SH, Lorenzetti BB, Cunha FQ, Poole S. Bradykinin release of TNFalpha plays a key role in the development of inflammatory hyperalgesia. Agents Actions 1993;38:7-9.
14. Khasar SG, Green PG, Levine JD. Comparison of intradermal and subcutaneous hyperalgesic effects of inflammatory mediators in the rat. Neurosci Lett 1993;153:215-8.
15. 9-bradykininmediated hyperalgesia in the rat by inflammatory stimuli. Braz J Med Biol Res 1994;27:1793-802.
16. Whalley ET, Clegg S, Stewart JM, Vavrek RJ. The effect of kinin agonists and antagonists on the pain response of the human blister base. Arch Pharmacol 1987;336:652-5.
17. Kingden-Milles D, Klement W. Pain and inflammation evoked in human skin by bradykinin receptor antagonists. Eur J Pharmacol 1992;218:183-5.
18. Birrell GJ, McQueen DS, Iggo A, Grubb BD. Prostanoid-induced potentiation of the excitatory and sensitizing effects of bradykinin on articular mechanonociceptors in the rat ankle joint. Neuroscience 1993;54:537-44.
19. Rueff A, Dray A. Sensitization of peripheral afferent fibres in the in vitro neonatal rat spinal cord-tail by bradykinin and prostaglandins. Neuroscience 1993;54:527-35.
20. Khan AA, Raja SN, Manning DC, Campbell JN, Meyer RA. The effects of bradykinin and sequence-related analogs on the response properties of cutaneous nociceptors in monkeys. Somatosens Mot Res 1991;9:97-106.
21. Vasko MR, Campbell WB, Waite KJ. Prostaglandin E2 enhances bradykininstimulated release of neuropeptides from rat sensory neurons in culture. J Neurosci 1994; 14:4987-97.
22. Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G, et al. Hoe 140, a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 1991;102:769-73.
23. Dray A, Perkins M. Bradykinin and inflammatory pain. Trends Neurosci 1993;16:99-104.
24. Steranka LR, Manning DC, DeHaas CJ. Bradykinin as a pain mediator: Receptors are localized to sensory neurons, and antagonists have analgesic actions. Proc Natl Acad Sci USA 1988;85:3245-9.
25. Heapy CG, Shaw JS, Farmer SC. Differential sensitivity of antinociceptive assays to the bradykinin antagonist Hoe 140. Br J Pharmacol 1993;108:209-13.
26. 2 receptor antagonists, des-Arg9, (Leu8)-BK and HOE 140, in two models of persistent hyperalgesia in the. Pain 1993;53:191-7.
27. 1 receptors in vivo in a model of ultra-violet irradiation-induced thermal hyperalgesia in the rat. Br J Pharmacol 1993; 110:1441-4.
28. 2 kinin receptors in formalin- induced nociceptive response in the mouse. Br J Pharmacol 1993;10:193-8.
29. Regoli D, Rhaleb NE, Drapeau G, Dion S. Kinin receptor subtypes. J Cardiovasc Pharmacol 1990;15:30-8.
30. 2 receptor mechanisms in cytokine-induced mechanical hyperalgesia in the rat. Br J Pharmacol 1994; 113:63-8.
31. 2 receptor agonists synergistically potentiate interleukin-1-induced prostaglandin biosynthesis in himan gingival fibroblasts. Inflammation 1991;15:427-36.
32. 1 agonist-induced PGI2 production. Br J Pharmacol 1994;113:389-94.
33. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692-6.
34. Seibert K, Masferrer JL. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor 1994;4:17-23.
35. Chammugam P, Feng L, Loliu S, Jang BC, Boudreau M, Yu G, et al. Radicicol, a protein tyrosine kinase inhibitor, suppresses the expression of mitogeninducible cyclooxygenase in macrophages stimulated with lipopolysaccharide and in experimental glomerulonephirtis. J Biol Chem 1995; 270:5418-26.
36. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994;91:12013-7.
37. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994;91:3228-32.
38. Tomlinson A, Appleton I, Moore AR, Gilroy DW, Willis D, Mitchell JA, et al. Cyclo-oxygenase and nitric oxide synthase isoforms in rat carrageenin-induced pleurisy. Br J Pharmacol 1994;113:693-8.
39. Endo T, Ogushi F, Sone S, Ogura T, Taketani Y, Hayashi Y, et al. Induction of cyclooxygenase-2 in responsible for interleukin-1 beta-dependent prostaglandin E2 synthesis by human lung fibroblasts. Am J Respir Cell Mol Biol 1995; 12:358-65.
40. Mitchell JA, Belvisi MG, Akarasereenont P, Robbins RA, Kwon OJ, Croxtall J, et al. Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br J Pharmacol 1994; 113:1008-14.
41. Tonussi CR, Ferreira SH. Mechanism of diclofenac anlagesia: direct blockade of inflammatory sensitization. Ear J Pharmacol 1994;251:173-9.
42. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducibel cyclooxygenase. Proc Natl Acad Sci USA 1993;90:11693-7.
43. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991;43:109-42.
44. Lamas S, Marsden PA, Li GK, Tempst P, Michel T. Endothelial nitric oxide synthase: Molecular cloning and characterization of a distinct constitutive enzyme isoform. Proc Natl Acad Sci USA 1992;89:6348-52.
45. Murphy S, Simmons ML, Agullo L, Garcia A, Feinstein DL, Galea E, et al. Synthesis of nitric oxide in CNS glial cells. Trends Neurosci 1993;16:323-8.
46. Minc-Golomb D, Tsarfaty I, Schwartz JP. Expression of inducible nitric oxide synthase by neurones following exposure to endotoxin and cytokine. Br J Pharmacol 1994; 112:720-2.
47. Dun NJ, Dun SL, Wu SY, Forstermann U, Schmitdt HHHW, Tseng LF. Nitric oxide synthase immunreactivity in the rat, mouse, cat and squirrel monkey spinal cord. Neuroscience 1993;54:845-57.
48. Aimi Y, Fujimara M, Vincent SR, Kimura H. Localization of NADPHdiaphorase-containing neurons in sensory ganglia of the rat. J Comp Neurol 1991;306:382-92.
49. Verge VMK, Xu A, Xu X-J, Wiesenfeld-Hallin Z, Hokfel T. Marked increase in nitric oxide synthase mRNA in rat dorsal root ganglia af ter peripheral axotomy: In situ hybridization and functional studies. Proc Natl Acad Sci USA 1992;89:11617-21.
50. Babbedge RC, Bland-Ward PA, Hart SL, Moore PK. Inhibition of rat cerebellar nitric oxide synthase by 7-nitro indazole and related substituted indazoles. Br J Pharmacol 1993;110:225-8.
51. G-nitro arginine p-nitroanilide (L-NAPNA) is antinociceptive in the mouse. Neurorepon 1993;4:307-10.
52. Moore PK, Babbedge RC, Wallace P, Gaffen ZA, Hart SL. 7-Nitro indazole, an inhibitor of nitric oxide synthase, exhibits anti-nociceptive activity in the mouse without increasing blood pressure. Br J Pharmacol 1993;108:296-7.
53. G-nitro arginine methyl ester exhibits antinociceptive activity in the mouse. Br J Pharmacol 1991;102:198-202.
54. Haley JE, Dickenson AH, Schachter M. Electrophysiological evidence for a role of nitric oxide in prolonged chemical nociception in the rat. Neuropharmacology 1992; 31:251-8.
55. Meller ST, Cummings CP, Traub RJ, Gebhart GF. The role of nitric oxide in the development and maintenance of the hyperalgesia produced by intraplantar injection of carrageenan in the rat. Neuroscience 1994;60:367-74.
56. Meiler ST, Pechman PS, Gebhart GF, Maves TJ. Nitric oxide mediates the thermal hyperalgesia produced in a model of neuropathic pain in the rat. Neuroscience 1992;50:7-10.
57. Wiesendfeld-Hallin Z, Hao J-X, Xu X-J, Hokfelt, T. Nitric oxide mediates ongoing discharges in dorsal root ganglion cells after peripheral nerve injury. J Neurophysiol 1993; 70:2350-3.
58. Holthusen H. Arndt JO. Nitric oxide evokes pain in humans on intracutaneous injection. Neurosci Lett 1994;165:71-4.
59. Kawahata A, Umeda N, Takagi H. L-arginine exerts a dual role in nociceptive processing in the brain: involvement of the kyotorphin-Met-enkephalin pathway and NO-cyclic GMP pathway. Br J Pharmacol 1993;109:73-9.
60. Kumar A, Raghubir R, Srimal RC, Dhawan BN. Evidence for involvement of nitric oxide in pretectal analgesia in rat. Neuroreport 1993;4:706-8.
61. Xu JY, Tseng LF. Increase of nitric oxide by L-arginine potentiates betaendorphin- but not mu-, delta- or kappa-opioid agonist-induced antinociception in the mouse. Eur J Pharmacol 1993;236:137-42.
62. Takagi H, Shiomi H, Ueda H, Amano H. A novel analgesic dipeptide from bovine brain is a possible Met-enkephalin releaser. Nature 1979;282:410-12.
63. Ren K, Williams GM, Ruda MA, Dubner R. Inflammation and hyperalgesia in rats neonatally treated with capsaicin: effects on two classes of nociceptive neurons in the superficial dorsal horn. Pain 1994;59:287-300.
64. Dray A. Neuropharmacological mechanisms of capsaicin and related substances. Biochem Pharmacol 1992;44:611-5.
65. Hayes AG, Skingle M, Tyers MB. Effects of single doses of capsaicin on nociceptive thresholds in the rodent. Neuropharmacology 1981;20:505-11.
66. Campbell EA, Bevan S, Dray A. Clinical applications of capsaicin and its analogues. In: Wood JN, ed. Capsaicin in the study of pain. London: Academic Press, 1993:255-72.
67. Rang HP, Bevan SJ, Dray A. Chemical activation of nociceptive peripheral neurones. Br Med Bull 1991; 47:534-48.
68. Lynn B. Capsaicin: actions on nociceptive C-fibres and therapeutic potential. Pain 1990;41:61-9.
69. ?. Br J Pharmacol 1991;102:77P.
70. Watson CP, Evans RJ. The postmastectomy pain syndrome and topical capsaicin: a randomized trial. Pain 1992; 51:375-9.
71. Cheshire WP, Snyder CR. Treatment of reflex sympathetic dystrophy with topical capsaicin. Case report. Pain 1990;42:307-11.
72. Watson CPN, Tyler KL, Bickers DR, Millikan LE, Smith S, Coleman E. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther 1993;15:510-26.
73. Wright JM. Review of the symptomatic treatment of diabetic neuropathy. Pharmacotherapy 1994;14:689-97.
74. Brand LL, Berman E, Schwen R, Loomans M, Janusz J, Bohne R, et al. NE-19550: a novel, orally active anti-inflammatory analgesic. Drugs Exp Clin Res 1987; 13:259-65.
75. Sietsema WK, Berman EF, Farmer RW, Maddin CS. The antinociceptive effect and pharmacokinetics of olvanil following oral and subcutaneous dosing in the mouse. Life Sci 1988;43:1385-91.
76. Maggi CA, Patacchini R, Rovero P, Giachetti A. Tachykinin receptors and tachykinin receptor antagonists. J Auton Pharmacol 1993;13:23-93.
77. Levine JD, Fields HL, Basbaum AI. Peptides and the primary afferent nociceptor. J Neurosci 1993;13:2273-86.
78. Urban L, Thompson SWN, Dray A. Modulation of spinal excitability: cooperation between neurokinin and excitatory amino acid neurotransmitters. Trends Neurosci 1994; 17:432-8.
79. Munro FE, Fleetwood-Walker SM, Parker RMC, Mitchell R. The effects of neurokinin receptor antagonists on mustard oil-evoked activation of rat dorsal horn neurons. Neuropeptides 1993;25:299-305.
80. Birch PJ, Harrison SM, Hayes AG, Rogers H, Tyers MB. The non-peptide NK1 receptor antagonist, (+/-)-CP-96,345, produces antinociceptive and anti-oedema effects in the rat. Br J Pharmacol 1992;105:508-10.
81. Courteix C, Bardin M, Chantelauze C, Lavarenne J, Eschalier A. Study of the sensitivity of diabetes-induced pain model in rats to a range of analgesics. Pain 1994;57:153-60.
82. Aanonsen LM, Wilcox GL. Nociceptive action of excitatory amino acids in the mouse: effects of spinally administered opioids, phencyclidine and sigma agonists. J Pharmacol Exp Ther 1987;243:9-19.
83. Cahusac PMB, Evans RH, Hill RG, Rodriguez RE, Smith ADS. The behavioural effects of an N-methylaspartate receptor antagonist following application to the lumbar spinal cord of concious rats. Neuropharmacology 1984; 123:719-24.
84. Haley JE, Sullivan AF, Dickenson AH. Evidence for spinal N-methyl-Daspartate receptor invovlement in prolonged chemical nociception in the rat. Brain Res 1990;518:218-26.
85. Ren K, Williams GM, Hylden JLK, Ruda MA, Dubner R. The effects of a noncompetitive NMDA rceptor antagonist, MK-801, on behavioral hyperalgesia and dorsal horn neuronal activity in rats with unilateral inflammation. Pain 1992;50:331-44.
86. Ren K, Williams GM, Hylden JLK, Ruda MA, Dubner R. The intrathecal administration of excitatory amino acid receptor antagonists selectively attenuate carrageenan-induced behavioral hyperalgesia in rats. Eur J Pharmacol 1992;219:235-43.
87. Davar G, Hama A, Deykin A, Vos B, Maciewicz R. MK-801 blocks the development of thermal induced hyperalgesia in a rat model of experimental painful neuropathy. Brain Res 1991;553:327-30.
88. Mao J, Price DD, Mayer DJ, Lu J, Hayes RL. Intrathecal MK-801 and local nerve anesthesia synergistically reduce nociceptive behaviors in rats with exeperimental mononeuropathy. Brain Res 1992;576:254-62.
89. Eisenberg E, Vos BP, Strassman AM. The NMDA antagonists Memantine blocks pain behavior in a rat model of formalin-induced facial pain. Pain 1993;54:301-7.
90. Kristensen JD, Karlsten R, Gordh T, Berge OG. The NMDA antagonist 3-(2carboxypiperazin-4yl)proyl-1-phosphonic acid (CPP) has antinociceptive effect after intrathecal injection in the rat. Pain 1994;56:59-67.
91. Kristensen JD, Svensson B, Gordh T. The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal adminstration in humans. Pain 1990;51:249-53.
92. Ault B, Hildebrand LM. L-glutamate activates peripheral nociceptors. Agents Actions 1993;39:142-4.
93. Ault B, Hildebrand LM. Activation of nociceptive reflexes by peripheral kainate receptors. J Pharmacol Exp Ther 1993;265:927-32.